The Valley Desk

Clinical trial reportFrontiers in immunologyPublished

Cost-per-responder analysis of patients with lenalidomide-refractory multiple myeloma receiving ciltacabtagene autoleucel in CARTITUDE-4

Read the publication ↗ Open access copy ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

Publication record

Type
Clinical trial report
Venue
Frontiers in immunology
Published
Subject terms
Humans; Multiple Myeloma; Thalidomide; Dexamethasone; Antineoplastic Combined Chemotherapy Protocols; Antibodies, Monoclonal; Treatment Outcome; Immunotherapy, Adoptive; Drug Resistance, Neoplasm; Aged; Middle Aged; Cost-Benefit Analysis
PubMed ID
39234256
PubMed Central ID
PMC11372240
Open access
Yes, open
Added to directory
Source checked

Report a correction or request removal